56 related articles for article (PubMed ID: 33956757)
1. Effectiveness of the combined MMRV Priorix-Tetra™ vaccine against varicella in a large Italian region: A case-control study.
Fortunato F; Musco A; Iannelli G; Meola M; Luigi Lopalco P; Martinelli D
Vaccine; 2024 Mar; 42(7):1608-1616. PubMed ID: 38341290
[TBL] [Abstract][Full Text] [Related]
2. Impact of pregnancy vaccine uptake and socio-demographic determinants on subsequent childhood Measles, Mumps and Rubella vaccine uptake: A UK birth cohort study.
Skirrow H; Foley K; Bedford H; Lewis C; Whittaker E; Costelloe C; Saxena S
Vaccine; 2024 Jan; 42(2):322-331. PubMed ID: 38072757
[TBL] [Abstract][Full Text] [Related]
3. Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps.
Fu C; Liang J; Wang M
Clin Vaccine Immunol; 2008 Sep; 15(9):1425-8. PubMed ID: 18667635
[TBL] [Abstract][Full Text] [Related]
4. Time to re-think measles vaccination schedule in India.
John TJ; Verghese VP
Indian J Med Res; 2011 Sep; 134(3):256-9. PubMed ID: 21985807
[No Abstract] [Full Text] [Related]
5. GSK's first-in-class antibiotic secures another phase III win, approaches regulatory run.
Mullard A
Nat Rev Drug Discov; 2024 Apr; 23(4):239. PubMed ID: 38459351
[No Abstract] [Full Text] [Related]
6. Effectiveness of "Priorix" Against Measles and Mumps Diseases in Children Born After 2004 in the United Kingdom: A Retrospective Case-control Study Using the Clinical Practice Research Datalink GOLD Database.
Povey M; Aris E; Cheuvart B; Hall G; Cohet C; Willame C
Pediatr Infect Dis J; 2021 Jun; 40(6):590-596. PubMed ID: 33956757
[TBL] [Abstract][Full Text] [Related]
7. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
8. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
12. Systematic literature review on the safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines.
Pereira P; Benninghoff B; Moerman L
Hum Vaccin Immunother; 2020 Nov; 16(11):2861-2872. PubMed ID: 32298219
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
